BioSpace News Archive

Kymera Therapeutics, Inc. today announced the appointment of Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary.

Axogen, Inc. today announced that Karen Zaderej, chairman, CEO, and president, will present at the JP Morgan 41st Annual Healthcare Conference in San Francisco.

Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, announced President and CEO Romesh Subramanian, Ph.D., will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023.

Arbor Biotechnologies will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 1:30 p.m. PT.

Lucira Health, Inc. announced the Canadian launch of Lucira Connect, a new virtual care program that allows Lucira test users the ability to test, learn about treatment options, access a telehealth consultation, and if appropriate, receive a prescription all from home for only the price of the test, excluding prescription costs.

Tonix Pharmaceuticals Holding Corp. today announced the appointment of Zeil Rosenberg, M.D., M.P.H. as its new Executive Vice President, Medical.

EyePoint Pharmaceuticals, Inc. today announced that Jay S. Duker, M.D., who has served as the company’s Chief Operating Officer (COO) since November 2021, has been promoted to the additional role of President.

Fulcrum Therapeutics, Inc.® announced that Robert J. Gould, Ph.D., former founding chief executive officer of Fulcrum and a current member of the Board of Directors, has been appointed interim chief executive officer, effective January 3, 2023.

Oncorus, Inc. and Daewoong Pharmaceutical Co., Ltd. (KRX: 069620), a leading South Korean pharmaceutical company, today announced a research collaboration for the discovery and development of novel lipid nanoparticle (LNP) formulations for mRNA drug candidates.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced the Investigational New Drug (IND) application filing for milciclib in combination with gemcitabine for non-small cell lung cancer (NSCLC).